The maker of the EpiPen just made a big change to the story it...


The pharmaceutical company Mylan, which makes the EpiPen, is now saying it understated the profits it derives from the life-saving allergy drug by 60% in a congressional hearing last week, according to The Wall Street Journal . The Journal reported, however, that Mylan "substantially reduced its calculation of EpiPen profits by applying the statutory US tax rate of 37.5%."



from Biotech News